140850: Intact N-Terminal Propeptide of Type 1 Procollagen

1. Melkko J, Kauppila S, Niemi S, et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem. 1996 Jun;42(6 Pt 1):947-954.8665688

2. Seibel MJ. Bone metabolism, mineral homeostasis and its pharmacological modulation. Clin Lab. 2004;50(5-6):255-264.15209433

3. Williams C, Sapra A. Osteoporosis markers. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. 2023 May 1.32644732

4. Reference intervals were established at the Powell Center for Esoteric Testing in Burlington, NC, by the Esoteric Immunoassay department.

5. Koivula MK, Risteli L, Risteli J. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum. Clin Biochem. 2012 Aug;45(12):920-927.22480789

6. Szulc P, Naylor K, Hoyle NR, Eastell R, Leary ET, National Bone Health Alliance Bone Turnover Marker Project. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int. 2017 Sep;28(9):2541-2556.28631236

7. Vasikaran S, Eastell R, Bruyère O, et al. Markers of boneturnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011 Feb;22(2):391-420.21184054

8. Bauer D, Krege J, Lane N, et al. National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int. 2012 Oct;23(10):2425-2433.22797491

9. Gillett MJ, Vasikaran SD, Inderjeeth CA. The role of PINP in diagnosis and management of metabolic bone disease. Clin Biochem Rev. 2021 Feb;42(1):3-10.34305208

10. Szulc P. Bone turnover: biology and assessment tools. Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):725-738.30449551

11. Greenblatt MB, Tsai JN, Wein MN. Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. Clin Chem. 2017 Feb;63(2):464-474.27940448

12. Johansson H, Odén A, Kanis JA, et al. A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int. 2014 May;94(5):560-567.24590144

13. Vasikaran SD, Chubb SAP, Schneider HG. Towards optimising the provision of laboratory services for bone turnover markers. Pathology. 2014 Jun;46(4):267-273.24798169

14. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 update. Endocr Pract. 2020 May;26(Suppl 1):1-46.32427503

15. Cabrera DC, Henríquez MS, Traba ML, Villafañe EA, de la Piedra C. Biochemical markers of bone formation in the study of postmenopausal osteoporosis. Osteoporosis Int. 1998;8(2):147-151.9666938

16. Saarto T, Blomqvist C, Risteli J, Risteli L, Sarna S, Elomaa I. Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients. Br J Cancer. 1998 Jul;78(2):240-245.9683300

17. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY study. J Bone Miner Res. 1999 Sep;14(9):1614-1621.10469291

18. Scariano JK, Garry PJ, Montoya GD, Duran-Valdez E, Baumgartner RN. Diagnostic efficacy of serum cross-linked N-telopeptide (NTx) and aminoterminal procollagen extension peptide (PINP) measurements for identifying elderly women with decreased bone mineral density. Scand J Clin Lab Invest. 2002;62(3):237-243.12088343

19. Scariano JK, Glew RH, Bou-Serhal CE, Clemens JD, Garry PJ, Baumgartner RN. Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women. Bone. 1998 Nov;23(5):471-477.9823455

20. Blumsohn A, Marin F, Nickelsen T, et al. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int. 2011 Jun;22(6):1935-1946.20938767

21. Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005 Jun;20(6):962-970.15883636

22. Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH. PINP as an aid for monitoring patients treated with teriparatide. Bone. 2011 Apr 1;48(4):798-803.21168536

23. Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004 Aug;19(8):1250-1258.15231011

24. Naylor KE, Jacques RM, Paggiosi M, et al. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int. 2016 Jan;27(1):21-31.25990354

25. Bell KJ, Hayen A, Glasziou P, et al. Potential usefulness of BMD and bone turnover monitoring of zoledronic acid therapy among women with osteoporosis: secondary analysis of randomized controlled trial data. J Bone MinerRes. 2016 Sep;31(9):1767-1773.27027655

26. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab. 2019 May 1;104(5):1595-1622.30907953

27. Naylor KE, McCloskey EV, Jacques RM, et al. Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis. Osteoporos Int. 2019 Apr;30(4):917-922.30613868

28. Garnero P, Stevens RE, Ayres SA, Phelps KV. Short-term effects of new synthetic conjugated estrogens on biochemical markers of bone turnover. J Clin Pharmacol. 2002 Mar;42(3):290-296.11865965

29. Diez-Perez A, Naylor KE, Abrahamsen, et al. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int. 2017 Mar;28(3):767-774.28093634

30. Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, Souberbielle JC. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int. 2000;11(4):295-303.10928218

31. Hannon R, Blumsohn A, Naylor K, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res. 1998 Jul;13(7):1124-1133.9661076

32. Peris P, Alvarez L, Monegal A, et al. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy. Bone. 1999 Sep;25(3):349-353.10495139

33. Reginster J-Y, Sarkar S, Zegels B, et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone. 2004 Feb;34(2):344-351.14962813

34. Sharp CA, Evans SF, Risteli L, Risteli J, Worsfold M, Davie MW. Effects of low- and conventional-dose transcutaneous HRT over 2 years on bone metabolism in younger and older postmenopausal women. Eur J Clin Invest. 1996 Sep;26(9):763-771.8889438

35. Suvanto-Luukkonen E, Risteli L, Sundström H, Penttinen J, Kauppila A, Risteli J. Comparison of three serum assays for bone collagen formation during postmenopausal estrogen-progestin therapy. Clin Chim Acta. 1997 Oct 31;266(2):105-116.9437539

36. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003 Sep 25;349(13):1207-1215.14500804

37. Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res. 2005 Nov;20(11):1905-1911.16234962

38. Ettinger B, San Martin J, Crans G, Pavo I. Differential effect of teriparatide on BMD after treatment with raloxifene and alendronate. J Bone Miner Res. 2004 May;19(5):745-751.15068497

39. Eastell R, Krege JH, Chen P, Glass EV, Reginster J-Y. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin. 2006 Jan;22(1):61-66.16393431

40. Liberman U, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in post menopausal osteoporosis. N Engl J Med. 1995 Nov 30;333(22):1437-1443.7477143

41. Stĕpán JJ, Vokrouhlická J. Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis. Clin Chim Acta. 1999 Oct;288(1-2):121-135.10529464

42. McClung M, San Martin J, Miller PD, et al. Opposite bone remodelling effects of teriparatide and alendronate in increasing bone mass. Arch Inter Med. 2005 Aug;165(15):1762-1768.16087825

43. Finkelstein JS, Leder BZ, Burnett SM, et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab. 2006 Aug;91(8):2882-2887.16684825

44. Heikkinen J, Vaheri R, Kainulainen P, Timonen U. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: A comparison of high- and low-dose estrogen-progestin regimens. Osteoporos Int. 2000;11(11):929-937.11193245

45. Heikkinen J, Vaheri RT, Ahomäki SM, Kainulainen PM, Viitanen AT, Timonen UM. Optimizing continuous-combined hormone replacement therapy for postmenopausal women: A comparison of six different treatment regimens. Am J Obstet Gynecol. 2000 Mar;182(3):560-567.10739508

46. Salam S, Gallagher O, Gossiel F, Paggiosi M, Khwaja A, Eastell R. Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy. J Am Soc Nephrol. 2018 May;29(5):1557-1565.29555831

47. Glendenning P, Chubb SAP, Vasikaran S. Clinical utility of bone turnover markers in the management of common metabolic bone diseases in adults. Clin Chim Acta. 2018 Jun;481:161-170.29544749

48. Al Nofal AA, Altayar O, BenKhadra K, et al. Bone turnover markers in Paget’s disease of the bone: a systematic review and meta-analysis. Osteoporos Int. 2015 Jul; 26(7):1875-1891.26037791

49. Alvarez L, Peris P, Pons F, et al. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget’s disease activity. Arthritis Rheum. 1997 Mar;40(3):461-468.9082934

50. Alvarez L, RicOs C, Peris P, et al. Components of biological variation of biochemical markers of bone turnover in Paget’s bone disease. Bone. 2000 Jun;26(6):571-576.10831927

51. Pons F, Alvarez L, Peris P, et al. Quantitative evaluation of bone scintigraphy in the assessment of Paget’s disease activity. Nucl Med Comm. 1999 Jun;20(6):525-528.10451864

52. Diaz-Martin MA, Traba ML, De La Piedra C, Guerrero R, Méndez-Dávila C, De La Peña EG. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma. Scand J Clin Lab Invest. 1999 Apr;59(2):125-132.10353326

53. Koizumi M, Yonese J, Fukui I, Ogata E. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int. 2001 Mar;87(4):348-351.11251528

54. Jukkola A, Bloigu R, Holli K, et al. Postoperative PINP in serum reflects metastatic potential and poor survival in node positive breast cancer. Anticancer Res. 2001 Jul-Aug;21(4B):2873-2876.11712779

55. Reference Change Value or RCV (also known as Least Significant Change) calculator. European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Biological Variation Database website: https://biologicalvariation.eu/meta_calculations). Updated March 29, 2024. Accessed May 2024.